Cargando…

Long-Term Treatment Outcomes in Type 3 Neovascularization: Focus on the Difference in Outcomes between Geographic Atrophy and Fibrotic Scarring

Background: To evaluate the difference in the long-term treatment outcomes of type 3 neovascularization between eyes with geographic atrophy and those with fibrotic scars. Methods: This retrospective study included 195 eyes diagnosed with type 3 neovascularization and treated with anti-vascular endo...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jae Hui, Kim, Jong Woo, Kim, Chul Gu, Lee, Dong Won
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230588/
https://www.ncbi.nlm.nih.gov/pubmed/32316276
http://dx.doi.org/10.3390/jcm9041145
_version_ 1783534989564968960
author Kim, Jae Hui
Kim, Jong Woo
Kim, Chul Gu
Lee, Dong Won
author_facet Kim, Jae Hui
Kim, Jong Woo
Kim, Chul Gu
Lee, Dong Won
author_sort Kim, Jae Hui
collection PubMed
description Background: To evaluate the difference in the long-term treatment outcomes of type 3 neovascularization between eyes with geographic atrophy and those with fibrotic scars. Methods: This retrospective study included 195 eyes diagnosed with type 3 neovascularization and treated with anti-vascular endothelial growth factor (VEGF) agents. The included eyes were divided into three groups according to the fundus findings at the final visit: patients with fovea-involving geographic atrophy (GA group), patients with fovea-involving fibrotic scars (scar group), and patients with no fovea-involving geographic atrophy or fibrotic scars (non-GA/scar group). The best-corrected visual acuities (BCVA) of the three groups at the final visits were compared. Results: The mean follow-up period was 47.5 ± 20.7 months. The mean logMAR BCVA at the final visit was 1.18 ± 0.58 in the GA group (n = 58), 1.67 ± 0.58 in the scar group (n = 62), and 0.69 ± 0.64 in the non-GA/scar group (n = 75). The BCVA was significantly worse in the scar group than in the GA (p < 0.001) and the non-GA/scar groups (p < 0.001). Conclusion: Eyes with fibrotic scars showed the poorest visual outcomes in type 3 neovascularization among the studied groups. Preventing the development of fibrotic scars should be considered an important treatment goal.
format Online
Article
Text
id pubmed-7230588
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72305882020-05-22 Long-Term Treatment Outcomes in Type 3 Neovascularization: Focus on the Difference in Outcomes between Geographic Atrophy and Fibrotic Scarring Kim, Jae Hui Kim, Jong Woo Kim, Chul Gu Lee, Dong Won J Clin Med Article Background: To evaluate the difference in the long-term treatment outcomes of type 3 neovascularization between eyes with geographic atrophy and those with fibrotic scars. Methods: This retrospective study included 195 eyes diagnosed with type 3 neovascularization and treated with anti-vascular endothelial growth factor (VEGF) agents. The included eyes were divided into three groups according to the fundus findings at the final visit: patients with fovea-involving geographic atrophy (GA group), patients with fovea-involving fibrotic scars (scar group), and patients with no fovea-involving geographic atrophy or fibrotic scars (non-GA/scar group). The best-corrected visual acuities (BCVA) of the three groups at the final visits were compared. Results: The mean follow-up period was 47.5 ± 20.7 months. The mean logMAR BCVA at the final visit was 1.18 ± 0.58 in the GA group (n = 58), 1.67 ± 0.58 in the scar group (n = 62), and 0.69 ± 0.64 in the non-GA/scar group (n = 75). The BCVA was significantly worse in the scar group than in the GA (p < 0.001) and the non-GA/scar groups (p < 0.001). Conclusion: Eyes with fibrotic scars showed the poorest visual outcomes in type 3 neovascularization among the studied groups. Preventing the development of fibrotic scars should be considered an important treatment goal. MDPI 2020-04-16 /pmc/articles/PMC7230588/ /pubmed/32316276 http://dx.doi.org/10.3390/jcm9041145 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Kim, Jae Hui
Kim, Jong Woo
Kim, Chul Gu
Lee, Dong Won
Long-Term Treatment Outcomes in Type 3 Neovascularization: Focus on the Difference in Outcomes between Geographic Atrophy and Fibrotic Scarring
title Long-Term Treatment Outcomes in Type 3 Neovascularization: Focus on the Difference in Outcomes between Geographic Atrophy and Fibrotic Scarring
title_full Long-Term Treatment Outcomes in Type 3 Neovascularization: Focus on the Difference in Outcomes between Geographic Atrophy and Fibrotic Scarring
title_fullStr Long-Term Treatment Outcomes in Type 3 Neovascularization: Focus on the Difference in Outcomes between Geographic Atrophy and Fibrotic Scarring
title_full_unstemmed Long-Term Treatment Outcomes in Type 3 Neovascularization: Focus on the Difference in Outcomes between Geographic Atrophy and Fibrotic Scarring
title_short Long-Term Treatment Outcomes in Type 3 Neovascularization: Focus on the Difference in Outcomes between Geographic Atrophy and Fibrotic Scarring
title_sort long-term treatment outcomes in type 3 neovascularization: focus on the difference in outcomes between geographic atrophy and fibrotic scarring
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230588/
https://www.ncbi.nlm.nih.gov/pubmed/32316276
http://dx.doi.org/10.3390/jcm9041145
work_keys_str_mv AT kimjaehui longtermtreatmentoutcomesintype3neovascularizationfocusonthedifferenceinoutcomesbetweengeographicatrophyandfibroticscarring
AT kimjongwoo longtermtreatmentoutcomesintype3neovascularizationfocusonthedifferenceinoutcomesbetweengeographicatrophyandfibroticscarring
AT kimchulgu longtermtreatmentoutcomesintype3neovascularizationfocusonthedifferenceinoutcomesbetweengeographicatrophyandfibroticscarring
AT leedongwon longtermtreatmentoutcomesintype3neovascularizationfocusonthedifferenceinoutcomesbetweengeographicatrophyandfibroticscarring